In short. Hydrating microdroplets, polynucleotides and cocktails are sold under one name, and their evidence is not interchangeable in any direction.
Key points
- It means there is a signal and the work is not yet mature.
- A reader may meet confident claims about these products, and the accurate response is not that the claims are false but that the body of evidence behind them is younger and thinner than the confident register suggests.
One name covers products that have almost nothing in common, and the reason is that the name describes a technique rather than a substance. Anything placed in small quantities across an area for the sake of skin quality can be called a booster, and that description fits a well-characterised substance and an unstandardised mixture equally well.
The injected hyaluronic acid class
This is the best-studied member of the group and the only one with a substantial record behind it. The substance is well characterised, its behaviour in tissue is understood, and the endpoints of hydration and skin quality are measurable. It is the member whose results are quoted when the category is described, which is precisely why the description is misleading.
Polynucleotides
A newer injected class with evidence that is real, narrower and more recent than the hyaluronic acid record. Availability varies by market, so a product that is routine in one country may be unapproved in another. It is graded as emerging here, and the grade is doing real work rather than hedging: the honest description is that these products are promising and less well documented than the substances they are often compared with.
Emerging is a real grade, not a diplomatic one
It means there is a signal and the work is not yet mature. A reader may meet confident claims about these products, and the accurate response is not that the claims are false but that the body of evidence behind them is younger and thinner than the confident register suggests.
The injected mixtures
Mixtures of vitamins and other additives are not standardised products, have no approved claim as a skin treatment in most markets, and have no body of evidence comparable to the injected hyaluronic acid class. The case made for them is usually a mechanism for each ingredient, which is a reason to study something rather than a result. Where a claim rests on the plausibility of the components, it has described a hypothesis.
The topicals
A topical product applies substances to the surface and is regulated as a cosmetic or a medicine according to the claims made for it. An injected product places substances in the tissue. They are different product classes with different regulation, different evidence and different risks, and the shared name is the only thing they have in common.
What the four groups share, and what they do not
- They share a name, a broad technique and a marketing position.
- They do not share a mechanism, a risk profile, an indication or a study.
- They are not interchangeable, and evidence does not transfer between them.
Naming the group a product belongs to is therefore the first and most useful step in reading any claim made about it.
Frequently asked questions
What kinds of product sit under this name?
At least four: injected hyaluronic acid placed as microdroplets, which is the best studied; injected polynucleotides, which are emerging and approved in some markets; injected mixtures of vitamins and other additives, which have no comparable evidence and no approved claim as a skin treatment in most markets; and topical products that share the name and are a different class entirely.
Why does one name cover products this different?
Because the name describes a technique rather than a substance. Anything delivered as small quantities across an area for skin quality can be called a booster, whether it is a well-characterised product with a long record or an unstandardised mixture with none. The name was available to everyone and it was used by everyone.
Can evidence for one be applied to another?
No. Evidence belongs to a product and an indication, and these products have not been required to show anything in common. A well-documented substance and an unapproved mixture can share a name without sharing a mechanism, a risk profile or a study. Applying the first one's record to the second is the central error in this category.
Risks & Limitations
- Skin booster is a category defined by how a substance is placed, so its members are not interchangeable and evidence does not transfer between them.
- The established evidence belongs to the injected hyaluronic acid class: hydration and skin quality, with microdroplet placement.
- Approval is per product and per market, and a product approved in one jurisdiction may not be approved in another.
- The effect is temporary, and maintaining it means repeating the treatment and repeating the risks.
- A booster does not add volume or lift tissue that has descended, and no injectable is approved to lift.
When to Seek Care
- Severe pain, or skin that becomes dusky, mottled or pale after an injection — seek emergency care immediately.
- A change in vision, or pain around the eye, after any injection to the face — seek emergency care immediately.
- A fever with spreading redness, or a lump that is painful and enlarging, is assessed by a clinician rather than watched.
- A rash, or nodules that appear or persist after an injection, are assessed by a clinician rather than treated further.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — approved injectable products and their labelled indications
- National Medical Products Administration (NMPA, China) — approved products and their indications
- European Medicines Agency (EMA) and national regulators — injectable product assessments
- Cochrane Library — systematic reviews of injectable skin treatments
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is a review of published evidence and regulation, not medical advice, and it does not cite individual studies. It is not a booking page and it does not recommend a product or treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.